Suresh S. Ramalingam, MD, Winship Cancer Institute

Articles by Suresh S. Ramalingam, MD, Winship Cancer Institute

The Future of Lung Cancer Treatment

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Fundamentals of Mesothelioma

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Latest Updated Articles

Trials in Limited-Stage Small-Cell Lung Cancer
October 26th 2020
Fundamentals of Mesothelioma
October 26th 2020
Recent Advances in Small-Cell Lung Cancer
October 26th 2020
Understanding Immune Response in Non–Small Cell Lung Cancer
October 26th 2020
Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer
October 26th 2020
Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer
October 26th 2020

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer